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The continued growth of solid neoplasms is always associated with neovasculariza- 
tion.  A  possible  mediator  is  tumorangiogenesis factor  (TAF),  an  endothelial cell 
mitogen which has been extracted from a variety of solid malignant tumors, in this 
laboratory  (1).  The  specific  blockade of  this factor,  "anti-angiogenesis,"  has  been 
proposed as a new approach to the control of malignant  growth (2, 3). 
The  consequences of  failure of  neovascularization for  tumor growth  have  been 
fortuitously observed in two experimental situations. In isolated perfused organs, in 
which endothelial cell degeneration has occurred (4) and new vessel outgrowth is not 
possible, tumor implants grow to a small size (2-3 mm diameter) but no further (5). 
Similarly, during experiments with heterologous tumor transplantation in guinea pig 
eyes (6),  Green observed that a few implants, which apparently did not vascularize, 
failed to grow for almost 2 yr. However, when these same tumors were  reimplanted 
into their original host, they vascularized and grew progressively. 
These observations suggested  that  a  fundamental relationship might exist 
between  angiogenesis and  the  ability of  a  tumor  to  grow  malignantly. The 
following experiments now provide in vivo evidence that the malignant growth 
of a homologous solid tumor can be deliberately arrested at a small size by pre- 
venting neovascularization. 
Materials and Methods 
Animals.--Male New Zealand white rabbits, initially 6 wk old and weighing 2-3 kg, were 
used for propagation of tumor stock and all experiments. 
Tumor.--A stock of Brown-Pearce rabbit epithelioma  1 was maintained by serial anterior 
chamber transfers. All stock and experimental iris implants yielded rapidly growing, richly 
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vascular tumors which demonstrated a characteristic pseudoacinar histology (7).  No instances 
of spontaneous regression were observed in serial passages through more than 12 generations 
(36 animals) during a 4 month period of observation (October through January). 
Implantation  Technique.--Intravenous  pentobarbital 2 anesthesia  (25  mg/kg)  was supple- 
mented by retrobulbar infiltration with 0.50  cc 2%  Xylocaine. a The eye was proptosed and 
secured in position by clamping a fold in the lower lid. Stock tumor was harvested from mature 
(10-14-day old) vascular iris implants and finely diced with iridectomy scissors in sterile saline 
at room temperature. Intraoeular implants were then performed in either of two ways.  4 
Vascular iris implants:  A small (2 mm)  peripheral corneal incision was made and a  small 
fragment of freshly minced tumor inserted with fine forceps. Care was taken  to  deposit  the 
implant directly on the iris at a  distance from the incision, which then closed spontaneousIy 
(Fig.  1). 
Avascular  anterior chamber implants:  A fresh tumor fragment was inserted into the anterior 
chamber via a central corneal incision. A coagulum routinely formed around the implant within 
the 1st few hours and subsequently retracted, tethering it to the inner surface of the corneal 
dome. These implants characteristically grew as small ovoid masses but remained suspended in 
the anterior chamber at a distance from the iris (Fig. 1). 
All procedures were performed under sterile conditions. No antibiotics or special eye care 
were given and intraocular infection was not observed. 
Measurement  of Tumor Growth.--Tumor implants were examined daily by two observers 
with the aid of a Zeiss slit lamp stereomicroscope (Carl Zeiss, Inc., New York), at  M  10-40 
magnification. Enface measurements of major and minor radii (X, Y) were obtained with an 
ocular micrometer at N  10 magnification (measurement error =t= 0.1 mm). The third dimension 
(Z) of iris implants (thickness) and anterior chamber implants (radius) was estimated by tan- 
gential viewing and  later corroborated  by measurement  of histologic sections of tumors at 
various stages of growth (applying +  20% shrinkage factor for fixation-dehydration artifact). 
Vascular iris implants appeared to grow as hemispheroids; therefore, daily volumes were 
estimated by the formula  V  -  (~)  ~r  (X)  (Y)  (Z)/2.  Avascular anterior chamber implants 
appeared to grow as spheroids; their volumes were estimated by the formula V  =  (~)Tr  (X) 
(V)  (Z). 
Cumulative  growth curves were  then  constructed  from  calculated  daily  tumor  volumes 
plotted on a  semilogarithmic scale. The rate of change of volume during different phases  of 
growth was estimated by the formula, Slope =  log~0V.., -- logtoV~/t.2 -- h. 
Demonstration  of Vascularlty.~ --The apparent onset of vascularization of small iris implants 
was  documented  in  vivo  by  use  of intravenous  Fluorescite  s  (0.5  cc/kg).  Perfused  tumors 
rapidly developed a green-yellow coloration when viewed under cobalt blue sllt lamp illumina- 
tion and thus were easily differentiated from prevascular iris implants or avascular anterior 
chamber implants which remained gray or pearly white, respectively. The reliability  of this 
test of vascularity was verified by histologic sampling at various stages of tumor growth. 
itlstologic  Studies.--Specimens  of iris tumor implants of various ages were fixed in  10% 
buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin. The smaller 
avascular anterior chamber implants were fixed whole by immersion in 2.5% glutaraldehyde- 
2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4)  for 4 hr, washed overnight in caco- 
2 Veterinary sodium pentoharbital (65 mg/ml), Samuel Perkins Co., Boston, .'~Iass. 
a Xylocaine  hydrochloride  (lidocaine),  Astra  Pharmaceutical  Products,  Inc.,  Worcester, 
Mass. 
4 We thank Dr. H. Zauberman (Retina Foundation, Boston) for his assistance in developing 
these techniques. 
5 Fluorescein  (5%)  in sterile  aqueous  solution,  Moore/Kirk  f,aboratories,  Inc.,  Hillside, 
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dylate buffer, postfixed in 1% osmium tetroxide, dehydrated, and embedded in Epon. 1-# thick 
Epon sections were then stained with i% toluidine blue. 
In some experiments, 0.4/zCi methyl-thymidine-aH (New England Nuclear Corp., Boston, 
Mass., specific activity 2 Ci/m~r)  in 0.2 cc of normal saline at 37°C was injected into the an- 
terior chamber, 45 rain before sacrifice. Radioautographs of histologic sections were then made 
according to standard techniques (8). 
RESULTS 
Vascular Iris Implanls.--Daily  sllt  lamp  observations  of  tumor  implants 
placed directly on the surface of the iris revealed a  consistent pattern in  all 
stock and experimental animals. These are represented schematically in Fig. 1. 
Day 1: Iris implant appears as a small, white sliver surrounded by a haze of 
fibrin. A mild iritis is present near the corneal incision which has sealed. 
Day 2: First evidence of growth is seen as a thin, gray cobblestoned coating 
covering the implant surface and adjacent iris. Iritis has resolved. 
Days 3-5: Implant continues to grow slowly as a thin, gray plaque. An in- 
tense,  localized  proliferation  of  small  iris  vessels  has  developed  around  its 
periphery. Fluorescein testing demonstrates increased perfuslon of this area of 
the iris,  but the implant plaque remains unperfused. 
Days 5-8: Vessels  are visible within  the implant,  which has increased sig- 
nificantly in size, forming a  thick, pink hemispherical mass. The surrounding 
iris develops corrugations and large vessels connect the implantation site with 
the limbus. Fluorescein testing readily demonstrates perfusion of the growing 
iris tumor. 
Days 8-12: Tumor size increases exponentially. The perillmbal  plexus be- 
comes engorged and long (2-3 mm) vascular loops grow into that portion of the 
cornea  overlying the  iris  tumor.  A  dense  network  of  engorged,  serpiginous 
vessels is evident over the entire iris. 
Days 12-14: Progressive growth results in a distortion of the pupil and gradu- 
ally the entire anterior chamber is filled by the vascular tumor mass. 
Days 15-16: A  dense,  circumferential outgrowth of corneal vessels has de- 
veloped, and corneal edema obscures the anterior chamber. The globe protrudes 
from the orbit and  unless the  experiment is terminated,  spontaneous: rupture 
occurs. 
A  histologic section of a  well-developed vascularized iris tumor  (day 8)  is 
illustrated  in  Fig.  2.  The iris  and  ciliary body have been infiltrated by the 
growing tumor. The tumor consists of anaplastic epithelial cells  and contains 
many small blood vessels (Fig. 3). 
The microscopic structure of an early implant  (day 3)  is seen in Fig. 4. A 
thin plaque of tumor cells  is seen on the surface of the iris.  The cells  appear 
well-preserved and mitotic figures are  seen.  Small  vessels are present  in  the 
subjacent iris,  but the tumor is not yet vascularized. 
When  calculated  daily  tumor volumes were plotted  on  a  semilogarithmic 
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Its sigmoid shape correlates with three distinct phases of tumor development. 
Phase I.-- 
Prevascular  (days  1  5):  The  small implant grows slowly (slope a)  as a  thin 
plaque, dependent upon diffusion for nutrient supply and catabolite removal. A 
Fro. 1.  The patterns of development of two simultaneous implants of Brown-Pearce tumor 
in the rabbit eye. The anterior chamber implant remains avascular and stops expanding at a 
small size, while the iris implant vascularizes and grows progressively. Inset demonstrates tech- 
nique of placing a small tumor fragment on iris through a peripheral corneal incision. 
neovascular response  is being  elicited from  adjacent host  tissues  but  the  im- 
plant is not yet perfused (negative fluorescein test). 
Phase II.-- 
Vascular  (days  6-11):  An  abrupt  change  in  growth  rate  (slope b)  is  noted 
once vascularization has occurred (positive fluorescein test). The perfused tumor 
then  begins  to  grow exponentially, doubling its volume  every  11.5  hr  on  the 
average (10 experiments). GIMBRONE,  LEAPMAN, COTRAN, AND  FOLKMAN  265 
l~hase lli.-- 
Late growth (days 12-14): As the volmne of tumor approaches that available 
in the anterior chamber, growth slows  (slope c). 
Slopes a, b, and c, for 10 iris implants, are tabulated in Table I. The rate of 
growth during the prevascular phase (slope a) is approximately one-tenth that 
during the vascular phase (slope b). The primary inflection of the growth curve 
(a to b)  is  seen to coincide in  each case with  the change from "negative" to 
"positive" in the fluorescein test, i.e., with vascularization of the implant. 
Volume doubling times,  (G)  --  log10  2/slope,  are summarized in Table II. 
Tumor volume doubled every 0.48 days (11.5  hr)  during the vascular phase, 
compared with every 4.95 days before vascularization (mean values for 10 ex- 
periments). 
At  14 days, vascular iris implants  had increased an  average of more than 
15,000 times their initial volume, in a series of 10 experiments (Table II). Mean 
final volmne was 331 mm  3, which approaches the total volume available in the 
anterior chamber of the rabbit eye. 
Avascular Anterior Chamber Implants.- 
Short term: The relative growth potential of avascular implants was initially 
studied by paired implantation of two comparable small pieces of tumor: in one 
eye, directly on the iris, and in the other, suspended in the anterior chamber. In 
every instance, iris implants vascularized and grew progressively as described 
above, forcing termination of the experiment within 14-16 days. In contrast, 
all anterior chamber implants failed to vascularize, remaining as small,  pearly 
white masses unperfused on fluorescein testing. 
Daily measurements often proved technically difficult during the 1st few days 
because of adherent fibrin strands. However, when early observations were pos- 
sible, two phases of growth were evident. During  the  1st 6-8 days, avascular 
implants tended to increase slightly in size, becoming ovoid in shape and covered 
with a gray cobblestoned cortex (as seen under X  40 magnification) ; a dormant 
period then followed during which no significant further increase  in size was 
noted (Fig. 1). 
A microscopic cross section of a typical avascular tumor (BP No. llL) early 
in this dormant period (day 7),  is seen in Fig. 6 A. A cortex of histologically 
well-preserved tumor cells surrounds a core of more vacuolated ceils,  some of 
which appear to be degenerated or frankly necrotic (Fig. 6 B). Mitotic figures 
are found in the outer layer. No vessels are present. The in vivo diameter was 
0.8 mm,  corresponding to a  calculated volume of 0.27 mm  3,  and had not in- 
creased during the 48 hr preceding sacrifice. 
At  14 days, avascular tumors had increased an average of four times their 
initial volume in a series of 10 experiments. Mean final volume was 0.56 mm  ~ 
(4-0.24 sn). 
This striking contrast between avascular and vascular tumor growth poten- 
tials is demonstrated graphically in Fig. 7. The mean daily volumes (4-SD) of 10 266 GIMBRONE~ LEAPMAN, COTRAN~ AND  FOLKMAN  267 
avascular anterior chamber implants are plotted on a linear scale over a  14 day 
period.  No  implant  attained  a  volume  greater  than  1  Into  3 during  this  time 
interval. A  typical iris implant growth curve (BP No. 29R) is superimposed for 
comparison.  Its  early growth,  during  the  prevascular phase  (days  1-5),  falls 
within the range of the avascular implants. However, once it has vascularized 
(positive fluorescein test on day 6), growth becomes exponential, enabling it to 
attain  a  final  volume  of  394  mm  3 (day  14),  approximately  16,000  times  its 
initial volume. 
Fie. 4.  Section through a "prevascular" tumor implant, showing a plaque of well-preserved 
tumor cells on the surface of the iris. C, cornea; I, iris. Approx. X 250. 
A vascular Anterior Chamber Implants.- 
Long term: In order to study the behavior of avascular tumors over a  longer 
period, "solitary" anterior chamber implants were made. However, even in this 
situation,  rapidly growing,  vascular  iris  tumors  developed,  presumably from 
cells  shed  during  the  initial  procedure  or  subsequently  from  the  viable  but 
FIG. 2.  Light micrograph  of a large vascularized  tumor 8 days after implantation on the 
iris. The tumor (T) has completely  replaced the iris proper and invaded the ciliary body. ANT, 
CH, anterior chamber; C, cornea; CP, ciliary processes. Stained with hemotoxylin and eosin, 
)<  15, 
FIG. 3.  A higher  magnification  of the vascularized  tumor. The epithelial tumor cells are 
anaulastic and exhibit numerous mitoses. B V, blood vessel. Approx. )< 400. 268  TUMOR  DORMANCY  IN  VIVO 
relatively dormant avascular implant. Therefore, certain implants were sterilely 
removed after  1~21  days' observation and reimplanted  in the anterior  cham- 
bers of fresh animals. In this manner, avascular tumors were followed for greater 
than 6 wk. 
A  direct comparison of final  to initial volumes in these  "second generation" 
implants is probably not valid because of the artifact of surgical reimplantation. 
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FIG. 5. The characteristic growth curve of an iris implant  (BP No. 29R) plotted on a semi- 
logarithmic scale. Positive fluorescein test on day 6 represents earliest evidence of perfusion of 
the tumor, and coincides with the beginning of exponential volume increase. Slopes "a," "b," 
and "c," corresponding to prevascular, vascular, and late phases of growth, are indicated. 
However, tumors followed for 16, 21, 34, and 44 days retained their ovoid shape 
and gray cobblestoned surface, but failed to increase significantly in size. Their 
final volumes averaged less than 0.5 mm  a. Avascularity remained  apparent on 
slit lamp examination  and was readily verified by fluorescein testing. 
Microscopic examination of cross sections of 16-, 34-, and 44-day old tumors 
confirmed their avascularity. These tumors consisted of a central core of necrotic 
cells and debris surrounded by layers of well-preserved  tumor cells (Fig. 8),  in 
which  occasional  mitotic  figures  were  seen  (Fig.  9).  In  those  experiments  in G1MBRONE~  LEAPMAN,  COTRAN,  AND  FOLKMAN 
TABLE  I 
Rates of Growth and Time of Vascularizatlon of 10 Irls Tumors 
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Experiment No. 
Growth curve slopes* 
(Prevascular)  (Vascular)  (Late) 
a  b  c 
Primary 
inflection 
(a to b) 
Vascu- 
lariza- 
tion~: 
day 
1  0.04  0.49  0.23  5-7 
2  0.05  0.68  0.14  5-6 
3  0.08  0.58  --  5-6 
4  0.03  0.96  0.14  6-7 
5  0.04  0.87  0.25  6-7 
6  0.16  0.54  0.13  4-6 
7  0.08  0.51  0.21  6-7 
8  0.19  0.70  0.15  5-6 
9  0.06  O. 64  O. 12  5-6 
10  0.12  0.56  0.12  5-7 
Mean4-sD  =  0.085  4-  0.055  0.65  4-  0.155  0.16  4-  0.051 
day 
7 
6 
6 
7 
7 
6 
7 
6 
6 
7 
* Estimated from semilogarithmic plots  (see text). 
"Positive" fluorescein test or gross appearance of tumor vessels. 
TABI,E  II 
Volume Doubling Times and Final Volumes of 10 Iris Tumors 
Experiment No. 
Volume doubling time* 
Prevascular  Vascular  Late 
Final  Final volume/ 
volume:~  initial volume§ 
days 
1  7.50  0.61  1.31 
2  6.00  0.44  2.15 
3  3.76  0.52  --- 
4  I0.0  0.31  2.15 
5  7.5  0.35  1.20 
6  1.9  0.56  2.32 
7  3.76  0.59  1.43 
8  1.58  0.43  2.00 
9  5.01  0.47  2.50 
i0  2.50  0.54  2.51 
sD  =  4.95  0.48  1.95 
4-2.00  -4-.019  4-0.176 
Mean-q- 
mm  ~ 
224  9,333 
306  6,008 
350  1,555 
230  38,333 
162  16,164 
400  33,333 
400  1,481 
368  12,270 
394  15,760 
480  4,800 
331  15,438 
4-153  4-3,546 
* Calculated time interval for doubling of tumor volume during 
late phases of growth, based on average rates of change of volume 
interval  (to  =  log10 2/slope). 
;~ Calculated tumor volume on day 14. 
§ Initial volume of implants averaged less than 0.10 mm  ~. 
prevascular, vascular, and 
(slopes a, b, c) during each 270  TUMOR DORMANCY IN  VIVO 
which thymidine-3H had been injected into the anterior chamber 45 min before 
sacrifice,  radioautographs of  growth-arrested  avascular  tumors demonstrated 
labeled nuclei in the peripheral cell layers (Fig. 10). 
The malignant growth  potential of  dormant-appearing 16-  and 34-day old 
tumors was demonstrated by reimplantation directly on the iris in fresh animals. 
FIG. 6.  (A) Cross section through an avascular anterior chamber tumor 7 days after im- 
plantation. The tmnor consists of a solid mass of cells which appear vacuolated  and  occa- 
sionally necrotic in the center (C) but well-preserved in periphery (P). The arrow  points to the 
coagulum stalk tethering the tumor to the corneal endothelium. 1 # thick Epon section stained 
with toluidine blue. M 110. (B)Higher magnification of the area outlined in Fig. 6 A showing 
transition between vacuolated and intact cells. 
After an initial prevascular phase, a vascular iris tumor developed, which grew 
rapidly, filling the anterior chamber. The histologic appearance of these reim- 
planted tumors was typical of any vascularized iris implant (Fig. 11). 
DISCUSSION 
These experiments provide in vivo evidence that prevention of neovasculari- 
zation can block the growth of a solid tumor at an early stage. It appears that 
vascularization permits an implant to enter exponential growth, while avascu- 
larity forces it to remain dormant at a small size. GIMBRONE,  LEAPMAN~ COTRAN, AND  FOLKMAN  271 
Avascular  carcinomas  were  created  by anterior chamber  implantation  in a 
susceptible rabbit strain. Unable to elicit  new capillary  ingrowth, these small 
spherical  tumors  appeared  to  survive  by  simple  diffusion,  suspended  in  the 
aqueous humor.  After  a  brief  period,  each ceased  growing at  a  diameter  less 
than 1 mm and then remained dormant for as long as 6 wk. That these avascu- 
lar spheroids were dormant, rather than necrotic, was demonstrated by (a) his- 
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FIG. 7.  A typical iris implant growth curve (BP No. 29R) and the mean daily volumes of 10 
avascular  anterior  chamber  implants  are plotted  on  a  linear  scale  for  comparison.  Positive 
fluorescein test on day 6 indicates time of vascularization of iris tumor. 
tologic sections that showed intact cells with thymidine-aH-labeled nuclei and 
mitotic figures in the periphery of the mass, and (b) their ability to grow rapidly 
when transplanted to a site where vascularization could occur. 
Control studies in which comparable small implants were placed directly on 
the iris  revealed that each passed through a prevascular growth phase early in 
its  course.  This  period was  objectively  defined  by  testing  for perfusion with 
intravenous  fluorescein.  A  sharp  inflection  in  the  growth  curve  of  each  iris 
implant correlated with the time of vascularization. Volume doubling times in 
the vascular phase averaged 11.5 hr, compared with 4.95 days in the prevascular 272  TUMOR  DORMANCY  IN  VIVO 
phase.  In  contrast,  the  growth  curves  of avascular  anterior  chamber  tumors 
reached  a  plateau  within  the range  of early prevascutar  iris  implants  and  re- 
mained there as long as neovascularization was prevented. 
The  fact  that  neovascularization  is  a  necessary  condition  for  malignant 
growth was again demonstrated when dormant avascular tumors were placed in 
FIG. 8.  (A) 1 /~ thick Epon section of an avascular tumor 34 days after implantation  into 
anterior chamber. Note the necrotic center (C) and cellular periphery  (P).  X 100. (B) Higher 
magnification of area outlined in Fig. 8 A, showing boundary between necrotic and intact cells. 
Stained with 1% toluidine blue. X 500. 
contact  with  the  iris.  Vascularization  was  followed  by  growth  to  several 
thousand times initial volume within 10-14 days. 
Histologic  sections  of  avascular  spheroids  revealed  several  layers  of  intact 
tumor cells, containing mitotic figures and thymidine-3I-Llabeled nuclei, cover- 
ing a core which became more necrotic in older implants.  This suggested that a 
balance of cell renewal  and cell death might exist in these dormant tumors. 
In the previous literature,  "dormancy" has been used  to refer to individual 
tumor cells which were thought to persist  "symbiotically" for long periods, bt~t GIMBRONE~  LEAPMAN, COTRAN~ AND  FOLKMAN  273 
FIG. 9.  1/z thick Epon section of tumor ceils from the periphery of an avascular tumor 16 
days after implantation. Note mitotic figure (arrow). X 400. 
FIG. 10.  Radioautograph of a 1/.~ thick Epon section taken from the periphery of an avascu- 
lar tumor 16 days after implantation and 45 min after injection of  thymidine-3H into  the 
anterior chamber, Note the large number of labeled nuclei.  X 400, 274  TUMOR  DORMANCY  IN  VIVO 
subsequently  could  be  stimulated  to malignant  growth  (9,  10).  Arrest  of  the 
cell cycle or special immunologic characteristics have been suggested as possible 
mechanisms  (11).  The  current  studies  provide  evidence for a  new concept of 
dormancy, the growth arrest of a population of neoplastic cells which does not 
become vascularized. Though a portion of its cells remain viable and mitotically 
active,  total  expansion  of  the  avascular  tumor  mass  ceases  at  a  small  size. 
Viewed in this light, dormancy need not be an attribute of a  tumor cell per se, 
but rather  that  of a  small  mass of tumor cells  which has failed  to vascularize 
and therefore cannot express its potential for malignant growth. 
In this way, spontaneous failure  of tumor neovascularization  could account 
for  clinical  instances  of  delayed  metastasis  or  local  recurrence.  Similarly,  in 
FIG. 11.  Hematoxylin-eosin section from an iris (I) on which an avascular anterior chamber 
tumor was implanted. The tumor (T) became vascularized and grew rapidly. X 200. 
those animal models in which surgical trauma,  wound healing,  or regeneration 
are  the  triggering  events  for  activation  of dormant  tumor  loci  (10,  12),  new 
vessel outgrowth may be playing an important role. 
It is unlikely that the dormancy of avascular tumors observed in this study 
is  the  result  of  immunologic mechanisms.  Cells  shed  from dormant  anterior 
chamber spheroids  were able  to develop into large tumors if they became im- 
planted on the iris and vascularized. Also avascular tumors transplanted into a 
fresh host showed no tendency to increase in size. 
Similarly,  this dormancy cannot be explained by some "growth inhibitor" in 
the aqueous humor. Iris implants were exposed, during their prevascular phase, 
to  the  same  milieu  as  avascular  tumors,  yet  remained  capable  of malignant 
growth. Also mitotic figures and  thvmidine-3H-labeled  tnmor cells were found 
on  the  surface  of  dormant  spheroids,  in  intimate  contact  with  the  aqueous 
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The mechanism of this population dormancy, occurring when neovasculariza- 
tion has been prevented, is not elucidated by these experiments. However, re- 
cent  studies  by Folkman  and  Hochberg,  6 in  this  laboratory,  suggest  an  ex- 
planation. Spheroidal colonies of malignant cells suspended in soft agar medium 
consistently stop expanding at a small size despite provision of fresh nutrient 
medium. Histologic sections of these growth-arrested spheres show a thin cortex 
of viable,  mitotically active cells  surrounding  a  necrotic core, similar  to  the 
avascular  tumors  described above. Radioactive thymidine labeling  reveals a 
progressive decrease in the DNA-synthetic cell fraction as these colonies ap- 
proach their maximum diameter. These authors propose that this reflects the 
accumulation of growth-inhibiting metabolites in a  diffusion-limited spherical 
mass.  These colonies thus  appear  to be  an  in  vitro analogue for the  small, 
dormant avascular tumors observed in the current study. 
Population dormancy,  therefore, appears  to be the fate of avascular  solid 
tumors. If neovascularization can be prevented, local malignant  growth  and 
perhaps distant metastasis (13) will not occur. These observations  thus suggest 
that  specific  blockade  of  tumor-induced  angiogenesis  would  be  effective  in 
controlling neoplastic growth. 
SUMMARY 
Dormant solid tumors were produced in vivo by prevention of neovasculari- 
zation. 
When small fragments of anaplastic Brown-Pearce carcinoma were implanted 
directly on the iris in susceptible rabbits, they always vascularized. A charac- 
teristic growth pattern, consisting of prevascular, vascular, and late phases, was 
observed, which terminated with destruction of the eye within 2 wk. The be- 
ginning of exponential volume increase was shown to coincide with vasculariza- 
tion of the implant, as demonstrated by perfusion with intravenous fluorescein 
and by histologic sections. 
In contrast, implants placed in the anterior chamber, at a distance from the 
iris,  did not become vascularized. After initial growth into spheroids, they re- 
mained arrested at  a  small  size comparable to prevascular iris implants,  for 
periods as long as 6 wk. Although dormant in terms of expansion, these avascu- 
lar tumors contained a population of viable and mitotically active tumor cells. 
When reimplanted on the iris,  vascularization was followed by rapid, invasive 
growth. 
These observations suggest that neovascularization is a necessary condition 
for malignant growth of a  solid tumor. When a  small mass  of tumor cells  is 
prevented from eliciting new vessel ingrowth from surrounding host  tissues, 
population dormancy results. These data suggest that the specific blockade of 
tumor-induced angiogenesis may be an effective means of controlling neoplastic 
growth. 
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